论文部分内容阅读
目的观察参芪扶正注射液联合NP方案在晚期非小细胞肺癌(NSCLC)中的疗效。方法所有病例均经病理和(或)细胞学确诊为晚期NSCLC。其中:治疗组42例行长春瑞滨(NVB)加顺铂(DDP)方案化疗,同时加用参芪扶正注射液;对照组26例单用NP化疗。参芪扶正注射液250ml, d1-10;NVB25mg/m2,d1,d8;DDP:30mg/m2d2-4,均静脉滴注。结果治疗组和对照组的总RR分别为28．6％和19．2％(P=0．003),总临床受益率(CBR)分别为71．4％和61．5％(P=0．0032),中位进展时间分别为6．2个月和4．9个月(P=0．06),治疗组与对照组化疗后的生活质量(QOL)评分比较有明显提高(P=0．008),毒副反应亦较轻(P=0．006)。结论参芪扶正注射液能明显改善晚期NSCLC的RR、CBR、QOL,并且能增效减毒,具有良好的应用价值。
Objective To observe the effect of Shenqi Fuzheng injection combined with NP regimen in advanced non-small cell lung cancer (NSCLC). Methods All cases were diagnosed as advanced NSCLC by pathology and / or cytology. Among them, 42 patients in the treatment group received vinorelbine (NVDP) plus cisplatin (DDP) regimen plus Shenqi Fuzheng injection while 26 in the control group received NP chemotherapy alone. Shenqi Fuzheng injection 250ml, d1-10; NVB25mg / m2, d1, d8; DDP: 30mg / m2d2-4, are intravenous drip. Results The total RR of treatment group and control group were 28.6% and 19.2%, respectively (P = 0.003). The overall clinical benefit rates (CBRs) were 71.4% and 61.5% (P = 0 .0032). The median time to progression was 6.2 months and 4.9 months respectively (P = 0.06). The quality of life (QOL) scores of the treatment group and the control group were significantly improved after chemotherapy (P = 0.008), toxic side effects are also lighter (P = 0.006). Conclusion Shenqi Fuzheng injection can significantly improve the RR, CBR, QOL of advanced NSCLC, and can increase efficiency and reduce toxicity, and has good application value.